Merck, a pharmaceutical company based in Kenilworth, New Jersey, announced that its PD-1 inhibitor pembrolizumab subcutaneous injection has been approved...
-
-
Recent Updates
- Merck’s PD-1 Inhibitor Pembrolizumab Subcutaneous Injection Approved in China
- Yiborui Releases AI Intelligent Agent Research Report: Consumer Willingness to Use Rises, Focus on “Authorization Management Mechanism”
- Sino Group and SVhk Launch ‘Inno-North’ Initiative in Hong Kong
- US Takes Stringent Approach in Regulating Chinese Automakers
- China’s Gwadar Port in Pakistan: A Plan Unfulfilled
- China’s New Measures to Boost Economy and Property Sector
- Breakthroughs in Biotech: Key Updates and Potential Impact
- Transport Corporation of India Announces ₹1,500 Crore Buyback and China Subsidiary
- Hangzhou’s Tech Companies Forge Strong Ties with Hong Kong for Global Expansion
- A Complete Guide To DeepSeek’s 2026 IPO: What It Means For China ETF KSTR
Blogroll